Urgently Announces First Quarter 2025 Financial Results

6 hours ago

Achieves Revenue In Line With Expectations With Record Gross MarginVIENNA, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Urgent.ly Inc. (Nasdaq:…

authID Reports Financial and Operating Results for the First Quarter Ended March 31, 2025

6 hours ago

DENVER, May 13, 2025 (GLOBE NEWSWIRE) -- authID® (Nasdaq: AUID) (“authID” or the “Company”), a leading provider of biometric identity verification…

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

6 hours ago

Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat…

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

6 hours ago

Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD)…

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

6 hours ago

- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill®…

Energous Wireless Power Solutions Reports First Quarter 2025 Results

6 hours ago

SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Energous Corporation d/b/a Energous Wireless Power Solutions (NASDAQ: WATT) (the “Company,”…

Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

6 hours ago

Revenue grew 37%, driven by increased product sales and service revenueREDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer,…

Gevo Reports First Quarter 2025 Financial Results

6 hours ago

Quarterly Revenue Increased $25 Million Compared to First Quarter of 2024 Due to Strategic Growth Initiatives  Further Revenue and Adjusted…

IZEA Reports Q1 2025 Revenue from Core Operations of $8.0 million, up 23%

6 hours ago

Improved Net Income by $3.1 million, achieving $(0.01) per share, Cash PositiveORLANDO, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- IZEA…

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

6 hours ago

Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in…

This website uses cookies.